[Federal Register Volume 83, Number 248 (Friday, December 28, 2018)]
[Notices]
[Pages 67440-67441]
[FR Doc No: 2018-28194]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-84897; File No. SR-ISE-2018-100]

Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing
and Immediate Effectiveness of Proposed Rule Change To Amend
Supplementary Material .02 to Rule 715

December 20, 2018.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on December 20, 2018, Nasdaq ISE, LLC (``ISE'' or ``Exchange'') filed
with the Securities and Exchange Commission (``SEC'' or ``Commission'')
the proposed rule change as described in Items I, II, and III, below,
which Items have been prepared by the Exchange. The Commission is
publishing this notice to solicit comments on the proposed rule change
from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend Supplementary Material .02 to Rule
715, which relates to Cancel and Replace Orders, to correct an
inadvertent error in the rule text.
    The text of the proposed rule change is available on the Exchange's
website at http://ise.cchwallstreet.com/, at the principal office of
the Exchange, and at the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Exchange recently filed a proposal to amend Supplementary
Material .02 to Rule 715 regarding Cancel and Replace Orders to correct
an inconsistency between the Exchange's rule text and the operation of
the System \3\ by removing the reference to Rule 710, which relates to
minimum price variations applicable to single leg options series traded
on the Exchange.\4\ The Exchange, however, inadvertently omitted the
deletion of Rule 722(c)(1) from this rule. Rule 722(c)(1) corresponds
to Rule 710 in that it relates to minimum price variations of complex
strategies. Accordingly, the Exchange is proposing herein to delete the
reference to Rule 722(c)(1) from Supplementary Material .02 to Rule
715.
---------------------------------------------------------------------------

    \3\ The term ``System'' means the electronic system operated by
the Exchange that receives and disseminates quotes, executes orders
and reports transactions. See Rule 100(a)(63).
    \4\ See Securities Exchange Act Release No. 84741 (December 6,
2018), 83 FR 63922 (December 12, 2018) (SR-ISE-2018-97).
---------------------------------------------------------------------------

    By way of background, a member currently has the option of either
sending in a cancel order and then separately sending in a new order
which serves as a replacement of the original order (two separate
messages), or sending a single cancel and replace order in one message
(i.e., a Cancel and Replace Order). Specifically, Supplementary
Material .02 to Rule 715 defines a Cancel and Replace Order as a single
message for the immediate cancellation of a previously received order
and the replacement of that order with a new order.\5\ The replacement
portion of the Cancel and Replace Order is treated as a new order and
as a result, goes through price or other reasonability checks conducted
by the System to validate such order against current market conditions
prior to proceeding with request to modify the order.\6\ If the
replacement portion of a Cancel and Replace Order does not satisfy the
System's price or other reasonability checks, the existing order will
be cancelled and not replaced. Accordingly, the reference to Rule 710,
which relates to minimum price variations applicable to single leg
options series traded on the Exchange, was deleted from Supplementary
Material .02 to Rule 715 as part of SR-ISE-2018-97, because Rule 710
does not involve the System considering the current market at the time
of the Cancel and Replace Order.\7\ The Exchange further explained in
SR-ISE-2018-97 that an incoming Cancel and Replace Order that fails the
minimum price variation checks in Rule 710 would not result in the
existing order being cancelled and not replaced.\8\ Accordingly, the
Exchange removed the reference to Rule 710 from the list of price or
other reasonability checks to conform its rule text to the System.
---------------------------------------------------------------------------

    \5\ If the previously placed order is already filled partially
or in its entirety, the replacement order is automatically cancelled
or reduced by the number of contracts that were executed. See
Supplementary Material .02 to Rule 715. Supplementary Material .02
to Rule 715 further provides how the replacement portion may retain
the priority of the original order, provided certain specified
conditions are met. The manner in which the Exchange treats priority
with respect to Cancel and Replace Orders is not changing under this
proposal.
    \6\ See Securities Exchange Act Release No. 80432 (April 11,
2017), 82 FR 18191 (April 17, 2017) (SR-ISE-2017-03) (memorializing
Cancel and Replace Orders in Supplementary Material .02 to Rule 715
as part of the Exchange's system migration to INET technology).
    \7\ See note 4 above.
    \8\ Id. In this instance, the System would simply reject the
cancel and replace message as an invalid instruction. The Exchange
notes that the previous T7 system likewise treated Cancel and
Replace Orders in this manner.
---------------------------------------------------------------------------

    As noted above, Rule 722(c)(1) relates to minimum price variations
of complex strategies, and is therefore analogous to the single leg
rule in ISE Rule 710. The Exchange therefore proposes to delete Rule
722(c)(1) from Supplementary Material .02 to Rule 715 for the same
reasons provided above for Rule 710. Similar to Rule 710, Rule
722(c)(1) does not involve the System considering the current market at
the time of the Cancel and Replace Order, and an incoming Cancel and
Replace Order that fails the minimum price variation checks for complex
strategies in Rule 722(c)(1) would likewise not result in the existing

order being cancelled and not replaced.\9\ As such, the Exchange
proposes to remove the reference to Rule 722(c)(1) from the list of
price or other reasonability checks to conform its rule text to the
System.
---------------------------------------------------------------------------

    \9\ Similar to Rule 710, the System would also simply reject the
cancel and replace message as an invalid instruction in this
instance. Furthermore, the previous T7 system likewise treated
Cancel and Replace Orders in this manner.
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that its proposal is consistent with Section
6(b) of the Act,\10\ in general, and furthers the objectives of Section
6(b)(5) of the Act,\11\ in particular, in that it is designed to
promote just and equitable principles of trade, to remove impediments
to and perfect the mechanism of a free and open market and a national
market system, and, in general to protect investors and the public
interest. The Exchange's proposal corrects an inadvertent error in
Supplementary Material .02 to Rule 715, which currently includes Rule
722(c)(1) within the list of price or other reasonability checks. As
discussed above, including Rule 722(c)(1) is inconsistent with the
operation of the Exchange's System because an incoming Cancel and
Replace Order which fails the minimum price variation checks in Rule
722(c)(1) does not result in the existing order getting cancelled and
not replaced. This rule change would amend the rule text to reflect
ISE's current practice, and should avoid potential confusion about how
the System processes Cancel and Replace Orders today.\12\
---------------------------------------------------------------------------

    \10\ 15 U.S.C. 78f(b).
    \11\ 15 U.S.C. 78f(b)(5).
    \12\ See note 9 above.
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition not necessary or appropriate in
furtherance of the purposes of the Act. The proposed rule change will
bring greater transparency to the Exchange's Rulebook, and therefore
does not unduly burden competition.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    No written comments were either solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not: (i)
Significantly affect the protection of investors or the public
interest; (ii) impose any significant burden on competition; and (iii)
become operative for 30 days from the date on which it was filed, or
such shorter time as the Commission may designate, it has become
effective pursuant to Section 19(b)(3)(A)(iii) of the Act \13\ and
subparagraph (f)(6) of Rule 19b-4 thereunder.\14\
---------------------------------------------------------------------------

    \13\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \14\ 17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)
requires a self-regulatory organization to give the Commission
written notice of its intent to file the proposed rule change at
least five business days prior to the date of filing of the proposed
rule change, or such shorter time as designated by the Commission.
The Exchange has satisfied this requirement.
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act. If the Commission
takes such action, the Commission shall institute proceedings to
determine whether the proposed rule should be approved or disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to<EMAIL_ADDRESS>Please include
File Number SR-ISE-2018-100 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.

All submissions should refer to File Number SR-ISE-2018-100. This file
number should be included on the subject line if email is used. To help
the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's internet website (http://www.sec.gov/rules/sro.shtml).
Copies of the submission, all subsequent amendments, all written
statements with respect to the proposed rule change that are filed with
the Commission, and all written communications relating to the proposed
rule change between the Commission and any person, other than those
that may be withheld from the public in accordance with the provisions
of 5 U.S.C. 552, will be available for website viewing and printing in
the Commission's Public Reference Room, 100 F Street NE, Washington, DC
20549, on official business days between the hours of 10:00 a.m. and
3:00 p.m. Copies of the filing also will be available for inspection
and copying at the principal office of the Exchange. All comments
received will be posted without change; the Commission does not edit
personal identifying information from submissions. You should submit
only information that you wish to make available publicly. All
submissions should refer to File Number SR-ISE-2018-100 and should be
submitted on or before January 18, 2019.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\15\
---------------------------------------------------------------------------

    \15\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Brent J. Fields,
Secretary.
[FR Doc. 2018-28194 Filed 12-27-18; 8:45 am]
 BILLING CODE 8011-01-P


[Federal Register Volume 86, Number 194 (Tuesday, October 12, 2021)]
[Notices]
[Pages 56699-56700]
[FR Doc No: 2021-22130]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings #1

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER21-2655-001.
    Applicants: Southwestern Public Service Company.
    Description: Tariff Amendment: SPS-Llano-Second Amnd-Deferral
Action-101-0.0.1 to be effective 12/31/9998.
    Filed Date: 10/5/21.
    Accession Number: 20211005-5061.
    Comment Date: 5 p.m. ET 10/26/21.

    Docket Numbers: ER22-42-000.
    Applicants: DTE Electric Company.
    Description: Sec.  205(d) Rate Filing: Amendment to Rate Schedule
28 to be effective 7/1/2021.
    Filed Date: 10/5/21.
    Accession Number: 20211005-5001.
    Comment Date: 5 p.m. ET 10/26/21.

    Docket Numbers: ER22-43-000.

    Applicants: American Electric Power Service Corporation, Indiana
Michigan Power Company, AEP Indiana Michigan Transmission Company,
Inc., PJM Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: American Electric Power
Service Corporation submits tariff filing per 35.13(a)(2)(iii: AEP
submits one FA re: SA No. 5677 to be effective 12/5/2021.
    Filed Date: 10/5/21.
    Accession Number: 20211005-5011.
    Comment Date: 5 p.m. ET 10/26/21.

    Docket Numbers: ER22-44-000.
    Applicants: Maverick Wind Project Holdings LLC.
    Description: Tariff Amendment: Notice of Cancellation of Market-
Based Rate Tariff to be effective 12/5/2021.
    Filed Date: 10/5/21.
    Accession Number: 20211005-5023.
    Comment Date: 5 p.m. ET 10/26/21.

    Docket Numbers: ER22-45-000.
    Applicants: California Independent System Operator Corporation.
    Description: Sec.  205(d) Rate Filing: 2021-10-05 EIM
Implementation Agreement Cancellation--BANC to be effective 12/5/2021.
    Filed Date: 10/5/21.
    Accession Number: 20211005-5077.
    Comment Date: 5 p.m. ET 10/26/21.

    Docket Numbers: ER22-46-000.
    Applicants: Parkway Generation Essex, LLC.
    Description: Baseline eTariff Filing: Market-Based Rate Application
and Request for Expedited Action to be effective 12/1/2021.
    Filed Date: 10/5/21.
    Accession Number: 20211005-5081.
    Comment Date: 5 p.m. ET 10/26/21.

    Docket Numbers: ER22-47-000.
    Applicants: Southwestern Electric Power Company.
    Description: Sec.  205(d) Rate Filing: SWEPCO-ETEC Loops Operations
Services Agreement to be effective 9/9/2021.
    Filed Date: 10/5/21.
    Accession Number: 20211005-5087.
    Comment Date: 5 p.m. ET 10/26/21.

    The filings are accessible in the Commission's eLibrary system
(https://elibrary.ferc.gov/idmws/search/fercgensearch.asp) by querying
the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: October 5, 2021.
Kimberly D. Bose,
Secretary.
[FR Doc. 2021-22130 Filed 10-8-21; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 80, Number 210 (Friday, October 30, 2015)]
[Proposed Rules]
[Pages 66850-66851]
[FR Doc No: 2015-27704]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 1271

[Docket No. FDA-2015-D-3581]

Homologous Use of Human Cells, Tissues, and Cellular and Tissue-
Based Products; Draft Guidance for Industry and Food and Drug
Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a draft document entitled ``Homologous Use of Human
Cells, Tissues, and Cellular and Tissue-Based Products; Draft Guidance
for Industry and FDA Staff.'' The draft guidance document provides
human cells, tissues, and cellular and tissue-based product (HCT/P)
manufacturers, health care providers, and FDA staff, with
recommendations for applying the criterion of ``homologous use'' as it
applies to HCT/Ps. The interpretation and application of the homologous
use criterion and related definitions have been of considerable
interest to industry stakeholders since they were first proposed during
the Agency's rulemaking on HCT/Ps.

DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by April 29, 2016.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to http://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on http://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2015-D-3581 for ``Homologous Use of Human Cells, Tissues, and
Cellular and Tissue-Based Products; Draft Guidance for Industry and FDA
Staff; Availability.'' Received comments will be placed in the docket
and, except for those submitted as ``Confidential Submissions,''
publicly viewable at http://www.regulations.gov or at the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION''. The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on http://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
    Submit written requests for single copies of the draft guidance to
the Office of Communication, Outreach and Development, Center for
Biologics Evaluation and Research (CBER), Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-
0002, or to the Office of the Center Director, Guidance and Policy
Development, Center for Devices and Radiological Health (CDRH), Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 66,

Rm. 5431, Silver Spring MD 20993-0002, or you may send an email request
to the Office of Combination Products at<EMAIL_ADDRESS>If you
are submitting a written request, send one self-addressed adhesive
label to assist the office in processing your requests. The draft
guidance may also be obtained by mail by calling CBER at 1-800-835-4709
or<PHONE_NUMBER>. See the SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Lori Churchyard, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911; or Angela Krueger, Office of Device Evaluation, Center for
Devices and Radiological Health, Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 66, Rm. 1666, Silver Spring, MD 20993-0002,
301-796-6380; or Leigh Hayes, Office of Combination Products, Office of
the Commissioner, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5125, Silver Spring, MD 20993-0002,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a draft document entitled
``Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based
Products; Draft Guidance for Industry and FDA Staff.'' The draft
guidance document provides HCT/P manufacturers, health care providers,
and FDA staff, with recommendations for applying the Sec.
1271.10(a)(2) (21 CFR 1271.10(a)(2)) criterion of homologous use. This
guidance will improve stakeholders' understanding of the definition of
homologous use in Sec.  1271.3(c), and how to apply the regulatory
criterion in Sec.  1271.10(a)(2) to their HCT/P.
    HCT/Ps are defined in Sec.  1271.3(d) as articles containing or
consisting of human cells or tissues that are intended for
implantation, transplantation, infusion, or transfer into a human
recipient. FDA has implemented a risk-based approach to the regulation
of HCT/Ps. Under the authority of section 361 of the Public Health
Service (PHS) Act (42 U.S.C. 264), FDA established regulations under
part 1271 for all HCT/Ps to prevent the introduction, transmission, and
spread of communicable diseases. HCT/Ps are regulated solely under
section 361 of the PHS Act and 21 CFR part 1271, if they meet the
criteria provided under Sec.  1271.10(a).
    If an HCT/P does not meet all of the criteria set out under Sec.
1271.10(a), and does not meet one of the exceptions in Sec.  1271.15,
the HCT/P will be regulated as a drug, device, and/or biological
product under the Federal Food, Drug, and Cosmetic Act, and/or section
351 of the PHS Act (42 U.S.C. 262).
    The draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent FDA's current thinking on ``Homologous Use of
Human Cells, Tissues, and Cellular and Tissue-Based Products.'' It does
not establish any rights for any person and is not binding on FDA or
the public. You can use an alternative approach if it satisfies the
requirement of the applicable statutes and regulations.
    In a separate document published elsewhere in this issue of the
Federal Register, FDA is announcing a public hearing entitled ``Draft
Guidances Relating to the Regulation of Human Cells, Tissues or
Cellular or Tissue-Based Products; Public Hearing; Request for
Comments'' to be held on April 13, 2016, to provide stakeholders with
the opportunity to discuss FDA's policy on regulation of HCT/Ps related
to the four draft guidances on the following topics: Homologous use,
same surgical procedure exception, minimal manipulation, and adipose
tissue.
    In separate documents published elsewhere in this issue of the
Federal Register, FDA is also reopening the comment periods to FDA's
public dockets on the previously issued draft guidance documents on the
following topics related to HCT/Ps: Minimal manipulation (Docket No.
FDA-2014-D-1696), adipose tissue (Docket No. FDA-2014-D-1856), and same
surgical procedure exception (Docket No. FDA-2014-D-1584).

II. Paperwork Reduction Act of 1995

    The draft guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in part 1271 have been approved under OMB
control number 0910-0543.

III. Electronic Access

    Persons with access to the Internet may obtain the draft guidance
at either http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm or http://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/default.htm or http://www.regulations.gov. Persons unable to download an electronic copy of
the draft guidance entitled ``Homologous Use of Human Cells, Tissues,
and Cellular and Tissue-Based Products; Draft Guidance for Industry and
FDA Staff'' may send an email request to<EMAIL_ADDRESS>to
receive an electronic copy of the document.

    Dated: October 27, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-27704 Filed 10-29-15; 8:45 am]
BILLING CODE 4164-01-P